The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 16, 2016
Filed:
May. 20, 2014
Applicant:
Boston Scientific Scimed, Inc., Maple Grove, MN (US);
Inventors:
Jianmin Li, Lexington, MA (US);
Michael Madden, Princeton, MA (US);
Assignee:
Boston Scientific Scimed, Inc., Maple Grove, MN (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/70 (2006.01); A61K 35/12 (2015.01); A61K 8/02 (2006.01); A61K 8/26 (2006.01); A61K 8/28 (2006.01); A61K 8/24 (2006.01); A61K 8/19 (2006.01); A61K 33/08 (2006.01); A61K 33/42 (2006.01); A61K 33/24 (2006.01); A61K 8/25 (2006.01); A61K 35/34 (2015.01); A61K 31/765 (2006.01); A61K 47/32 (2006.01); A61Q 90/00 (2009.01); A61Q 19/00 (2006.01); A61L 27/50 (2006.01); A61K 33/44 (2006.01); A61F 2/00 (2006.01); A61K 35/33 (2015.01); A61K 33/34 (2006.01);
U.S. Cl.
CPC ...
A61K 9/70 (2013.01); A61F 2/0036 (2013.01); A61K 8/02 (2013.01); A61K 8/0204 (2013.01); A61K 8/027 (2013.01); A61K 8/19 (2013.01); A61K 8/24 (2013.01); A61K 8/25 (2013.01); A61K 8/26 (2013.01); A61K 8/28 (2013.01); A61K 31/765 (2013.01); A61K 33/08 (2013.01); A61K 33/24 (2013.01); A61K 33/34 (2013.01); A61K 33/42 (2013.01); A61K 35/12 (2013.01); A61K 35/33 (2013.01); A61K 47/32 (2013.01); A61L 27/50 (2013.01); A61Q 19/00 (2013.01); A61Q 90/00 (2013.01); A61K 33/44 (2013.01); A61K 2800/91 (2013.01); A61L 2400/06 (2013.01);
Abstract
According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.